Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas
Blood Research
;
: 187-192, 2016.
Article
in English
| WPRIM
| ID: wpr-209254
ABSTRACT
BACKGROUND:
This study aimed to assess the treatment outcomes of ifosphamide, mesna, etoposide, and prednisolone (IMEP) combination regimen as a front-line chemotherapy in patients with peripheral T-cell lymphomas (PTCLs).METHODS:
Clinical data of 38 newly diagnosed PTCLs patients who underwent IMEP at Busan Paik Hospital from January 2002 to December 2013 were retrospectively analyzed.RESULTS:
The overall response rate was 68.5%, with 21 (55.3%) complete response/complete response unconfirmed and 6 (15.8%) partial response (PR). The median follow-up duration was 25.5 months (range, 0.2-87.3). The median overall survival was not reached and 2-year survival rate was 67%. The median progression free survival was 23 months. The most frequently reported adverse effects higher than grade 3 were hematologic toxicities including neutropenia (68.4%), thrombocytopenia (42.1%). There was no treatment-related mortality.CONCLUSION:
IMEP regimen is effective and safe as a front-line chemotherapy in patients with PTCLs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thrombocytopenia
/
Prednisolone
/
Survival Rate
/
Retrospective Studies
/
Follow-Up Studies
/
Mortality
/
Lymphoma, T-Cell, Peripheral
/
Mesna
/
Disease-Free Survival
/
Drug Therapy
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Blood Research
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS